Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    74,846

Sanofi SA News & Analysis

stocks

6 undervalued US shares that crushed earnings

Atlassian and CarMax remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance

Can you achieve global diversification with multinational companies?

A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,955.01125.73-1.56%
DAX 4024,886.51577.30-2.27%
Dow JONES (US)49,079.2917.77-0.04%
FTSE 10010,373.0179.67-0.76%
HKSE22,410.80430.82-1.89%
NASDAQ23,225.76653.44-2.74%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5007,070.99104.84-1.46%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers